Abstract 1194P
Background
Neuroendocrine tumors of the appendix are typically detected incidentally during appendectomy. A recent study reported no cases of metachronous metastases among patients with primary tumors <2cm, regardless of lymph node status or referral for completion hemicolectomy. However, questions persist regarding the possibility of metastases developing decades after surgery, particularly since appendiceal NETs are frequently diagnosed in young adults and children.We therefore sought to evaluate patients with metastatic appendiceal NETs to assess whether any had been diagnosed previously with an early stage appendiceal NET.
Methods
We analyzed a large institutional neuroendocrine tumor database to identify appendiceal NETs of all stages and ascertain whether any patients with localized tumors developed metastases, and whether any with metastatic disease had originally presented with an early-stage tumor.
Results
Out of over 5,000 patients seen in the neuroendocrine tumor clinic between 2008 and 2022, 95 were diagnosed with an appendiceal NET. Of these, only 6 patients (approximately 0.1% of total NET population) had stage 4 metastases, all diagnosed synchronously at time of initial diagnosis. All 6 patients had peritoneal disease. No patient with earlier-stage disease developed distant metastases.
Conclusions
Metastatic appendiceal NETs are exceptionally rare with a tendency to metastasize within the peritoneum. In all cases of stage 4 disease, metastases were observed at time of diagnosis. Our data provide further validation for the proposition that small local appendiceal NETs resected during appendectomy require no further surgery or surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Strosberg: Financial Interests, Personal, Speaker’s Bureau: Ipsen, Tersera; Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1170P - Survival outcome prediction of primary melanoma tumours from histology images using deep learning
Presenter: Céline Bossard
Session: Poster session 13
1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Presenter: Jorge Bartolome
Session: Poster session 13
1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Presenter: Marin Golcic
Session: Poster session 13
1173P - NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma
Presenter: Yu Xu
Session: Poster session 13
1174P - Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Presenter: Eva Muñoz Couselo
Session: Poster session 13
1175P - Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
Presenter: Judith Lijnsvelt
Session: Poster session 13
1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Presenter: Anna Czarnecka
Session: Poster session 13
1177P - Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
Presenter: Ralf Gutzmer
Session: Poster session 13
1178P - Melanoma incidence rises for pediatrics: 15-year nationwide retrospective cohort study in Korea (2004-2019)
Presenter: Jisu Oh
Session: Poster session 13
1179P - The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients
Presenter: Amr Ehab El-Qushayri
Session: Poster session 13